MariMed (MRMD) Chief Commercial Officer reports 54,000 RSUs vested and tax withholding

Rhea-AI Filing Summary

MariMed Inc.'s Chief Commercial Officer reported routine equity compensation activity. On 12/08/2025, 54,000 restricted stock units (RSUs) converted into the same number of shares of common stock at an exercise price of $0, increasing his directly held shares to 838,925.

On the same date, 15,850 shares of common stock were withheld by MariMed at a price of $0.0824 per share to cover tax obligations related to the RSU vesting, leaving the officer with 823,075 shares held directly after these transactions. The RSUs convert to common stock on a one-for-one basis.

The filing notes that these RSUs were originally granted on June 8, 2023, and that the remaining 54,000 RSUs from this grant are scheduled to vest on June 8, 2026, under an award agreement between MariMed and the reporting officer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crandall Ryan

(Last) (First) (Middle)

10 OCEANA WAY, 2ND FLOOR

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	12/08/2025		M		54,000	A	$0(1)	838,925	D
Common stock	12/08/2025		F		15,850(2)	D	$0.0824	823,075	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSU)	(1)	12/08/2025		M			54,000	(3)	(3)	Common Stock, par value $.001 per share	54,000	$0	54,000	D

Explanation of Responses:

1. RSUs convert to shares of common stock on a one-for-one basis.

2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.

3. These RSUs were granted on June 8, 2023; the remaining RSUs under this grant will vest on June 8, 2026, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.

Remarks:

	/s/ Ryan Crandall	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MariMed (MRMD) report in this Form 4?

The Chief Commercial Officer of MariMed Inc. (MRMD) reported the vesting and conversion of 54,000 RSUs into common stock on 12/08/2025, along with share withholding to cover taxes.

How many MariMed (MRMD) shares did the officer own after the reported transactions?

After the RSU conversion and tax withholding, the officer directly owned 823,075 shares of MariMed common stock.

What amount of MariMed (MRMD) stock was withheld for taxes in this filing?

15,850 shares of MariMed common stock were withheld by the company at a price of $0.0824 per share to satisfy tax withholding obligations associated with the RSU vesting.

What are the terms of the RSUs reported by MariMed (MRMD)?

The restricted stock units (RSUs) convert to common stock on a one-for-one basis. They were granted on June 8, 2023, and the remaining 54,000 RSUs from this grant are scheduled to vest on June 8, 2026.

What position does the reporting person hold at MariMed (MRMD)?

The reporting person is an officer of MariMed Inc., serving as the company’s Chief Commercial Officer.

Is this MariMed (MRMD) Form 4 filed by one or multiple reporting persons?

This Form 4 is indicated as being filed by one reporting person, not a group filing.